Cost-comparison analysis of bendamustine, rituximab, etoposide and carboplatin (TREC) vs. RICE/R-DHAP in relapsed lymphoma. This is an ASCO Meeting Abstract from the 2015 ASCO Annual Meeting I. This ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results